Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation
Concentration‐QTcF data obtained from two phase I studies in healthy volunteers treated with a novel phosphodiesterase‐4 inhibitor currently under development for the treatment of chronic obstructive pulmonary disease were analyzed by means of mixed‐effects modeling. A simple linear mixed‐effects mo...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-07-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.12405 |